Primary Health Properties — Update 26 August 2016

Primary Health Properties (LSE: PHP)

Last close As at 27/03/2024

GBP0.95

0.65 (0.69%)

Market capitalisation

GBP1,261m

More on this equity

Research: Real Estate

Primary Health Properties — Update 26 August 2016

Primary Health Properties

Martyn King

Written by

Martyn King

Director, Financials

Real Estate

Primary Health Properties

Secure and growing income

H116 results and outlook

Real estate

26 August 2016

Price

112p

Market cap

£669m

Net debt (£m) at 30 June 2016

694.6

Shares in issue

597.2m

Free float

98%

Code

PHP

Primary exchange

LSE

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

3.9

8.2

9.6

Rel (local)

0.9

(3.4)

3.1

52-week high/low

114.5p

94.9p

Business description

Primary Health Properties is a long-term investor in primary healthcare property in the UK and, recently, Ireland. Assets are mainly long-let to GPs and the NHS or the HSE, organisations backed by the UK and Irish governments respectively. The tenant profile and long average lease duration provide an exceptionally secure rental income stream.

Next events

Quarterly dividend paid

August 2016

Quarterly dividend paid

November 2016

Year end

31 December 2016

Analysts

Martyn King

+44 (0)20 3077 5745

Julian Roberts

+44 (0)20 3077 5748

Primary Health Properties is a research client of Edison Investment Research Limited

The first half of FY16 saw Primary Health Properties (PHP) continuing to grow on all key metrics. The low-cost operating model should see ongoing portfolio growth translate into rising earnings and dividend paying capacity. Consensus is that PHP will pay 5.125p in earnings in FY16, which would be the 20th year of unbroken dividend growth. Our increased estimates indicate that dividends will remain fully covered despite an increased share count from the April capital increase. PHP offers an attractive, growing and secure dividend, supported by predictable long-term cash flows from mainly government-backed revenues.

Year end

Revenue (£m)

EPRA earnings*
(£m)

EPS*
(p)

DPS
(p)

Yield
(%)

EPRA NAV per share (p)

12/14

60.0

18.2

4.1

4.875

4.4

79.7

12/15

63.1

21.7

4.9

5.000

4.5

87.7

12/16e

67.2

27.1

4.8**

5.125

4.6

91.6

12/17e

72.9

32.3

5.4

5.250

4.7

94.8

Note: *PBT and EPS are on an underlying EPRA basis, excluding valuation movements and other exceptional items. **Using weighted average shares for the year. Total cash dividend covered fully by earnings.

Funded for continuing growth

EPRA earnings grew by 27.3% in H116 to £12.6m, or by 9.1% to 2.4p in per-share terms, calculated including the impact of the increased number of shares in issue following the April capital increase, which added £150m in new equity to support ongoing growth. After payment of 2.5625p in dividends (up 2.5%), EPRA NAV per share increased 3.1% to 90.4p, benefiting from revaluation gains as yields tightened further (asset prices rose). With the new shares ineligible for the H116 dividend, cover was 110%; we expect this to re-balance for the year as a whole as these shares receive a dividend in the second half and look for cover to be maintained as the new funds are deployed. Our increased earnings estimates reflect operational gains (faster asset growth on a low-cost structure) and lower financial costs (lower average debt and the impact of debt swap renegotiation).

Economically insensitive growth potential

The primary healthcare property markets in both the UK and Republic of Ireland (RoI) provide a strong medium- to long-term growth outlook, driven by ageing populations with growing healthcare needs, underinvested primary healthcare estates and a general acceptance of the need for more integrated primary care services in the community, improving care and efficiency. Both require modern, purpose-built, flexible premises of the type in which PHP invests. In contrast to the broad commercial property sector, tenant demand is not economically sensitive, leases are long, vacancy is minimal and the tenant covenant is unusually strong.

Valuation: Secure and growing dividends

PHP’s progressive dividend is attractive and secure with c 91% of current rents derived directly or indirectly from the UK government, with no material linkage to the economic cycle. As a result, healthcare property values have shown much less volatility than the broad commercial sector.

Secure and growing income

Interim results for the six months to 30 June 2016 showed continued progress in assets, rental income, profitability, dividends and net asset value. In April 2016 gross proceeds of £150m were raised from both existing and new shareholders in an oversubscribed issue at 100p per share, a 14% premium to the FY15 EPRA NAV per share, and therefore NAV accretive. The proceeds reduced the interim LTV to 53% and are primarily earmarked for further accretive portfolio growth. H116 saw £54m deployed in immediately income-generating let properties, in addition to investment in asset management initiatives and ongoing development commitments. Management reported a robust pipeline of potential acquisitions in both the UK and Ireland, including its first Irish investment, the contract for which is expected in August 2016. While valuation yields have continued to tighten marginally (asset prices have increased), favourable lending conditions and PHP’s reducing marginal administrative costs have maintained an attractive yield spread. A renegotiation of expensive interest rate swap contracts with a nominal value of £88m will usefully reduce PHP’s ongoing cost of debt with effect from November, albeit substantially offset in cash flow terms by a one-off settlement funded by the NAV premium realised on the April 2016 equity issue. H116 confirmed the return to full dividend cover that was achieved in H215 and while we expect a dip in H216 as the new equity is fully put to work, and interest savings work through, we expect full dividend cover for the year and for FY17. In this report we provide an update on recent developments and forecasts but we also provide a full examination of PHP’s strategy and prospects and the primary healthcare markets in the UK and RoI in which PHP operates.

Highlights of the first-half results

PHP acquired 19 let properties in the UK in the first half of the year for £54m, taking the portfolio to 292 properties with a value of £1,198m. Of these, 289 properties were complete and rent-producing and three were on-site under construction (two now completed). £12.5m was invested in respect of existing development commitments during the period. The acquired properties added c £3.0m to the rent roll, which reached £66.9m (31 December: £63.7m) with the usual effective full occupancy (99.7%). The weighted average unexpired lease term was 14.1 years (31 December: 14.7 years). 91% of rental income comes directly or indirectly (through GP reimbursement) from the UK government with a further 8% from co-located pharmacies.

Since the half-year end, PHP entered into its first conditional contract to acquire a primary care centre under development in the RoI for a consideration of €6.7m. Contract completion is expected to take place in August, when construction is also scheduled to finish. The asset will be fully let on completion: 75% to the Health Service Executive (HSE), 22% to a major Irish pharmacy chain and the remainder to local GPs. Although in the RoI GPs’ rents are not reimbursed by the state, the fact that the HSE itself will be the main tenant provides a strong tenant covenant, as is the case in the UK.

The 30 June 2016 investment portfolio value of £1.2bn (up 7.9% from £1.1bn at 1 January) was externally assessed and includes development properties. Adjusting for acquisitions, like-for-like growth was 1.85% with a net valuation gain after costs associated with acquisitions of £15.5m and the impact of the stamp duty increase in H116. The main driver of valuation growth was a further marginal tightening of yields in the primary care sector with some additional support from rental growth. The net initial yield as at 30 June was 5.21%, compared with 5.32% at 31 December 2015.

Rental income grew 5.2% to £32.2m (H115: £30.6m) mainly reflecting portfolio acquisitions and development completions. Average rental growth of 1.0% was secured on the 82 rent reviews that closed during the period, down on the prior year period (1.1%) but up on 2015 as a whole (0.9%).

Administrative costs increased by 4.1% year-on-year (3.9% on an EPRA basis) due to portfolio growth but below the 5.2% increase in net rental income. The EPRA basis cost ratio remains the lowest in the sector at 11.5%.

EPRA earnings grew 27.3% to £12.6m (H115: £9.9m) and, allowing for the increased number of shares in issue, EPRA EPS rose 9.1% to 2.4p (H115: 2.2p). Statutory IFRS profit before tax was lower compared with the same period last year (£25.4m versus £32.4m) reflecting a lower year-on-year net revaluation gain.

Aggregate dividends of 2.5625p per share were paid in H116, 2.5% up on H115. A third quarterly dividend of 1.28125p will be paid on 26 August, and consensus forecasts see PHP paying a total of 5.125p in dividends for the year as a whole (the 20th year of unbroken dividend growth). H116 dividends were fully covered by earnings (110% cover versus 98% in H115) with the increase in cover partly reflecting the fact that the new shares issued were ineligible for the H116 dividends. Our forecasts indicate full cover on a full year 2016 basis (101%), increasing in 2017 (103%) as the capital raising proceeds are more fully deployed.

After dividend payments, EPRA NAV per share rose 3.1% to 90.4p (31 December 2015: 87.7p). Adding back the dividend payments, NAV total return has been 6.0% since 31 December 2015 and 9.5% over the 12 months to 30 June 2016. Total shareholder return (the share price movement plus dividends) during H116 was affected by market volatility linked to the EU referendum. At 0.5% in the six months to 30 June it was lower than the 4.3% total return on the FTSE All Share Index but noticeably robust in a property sector that was more than averagely affected by the Brexit vote towards the June month end (the EPRA NAREIT UK Index was down 15% over H116). The PHP total return over 12 months to 30 June 2016 was 8.5% versus 2.2% for the FTSE All Share. Since 30 June to date of this report, the PHP share price has risen c 6% from 105.75p to 112p.

In April 2016 PHP completed a capital issue, raising £150m of gross proceeds (£143.5m net) in an oversubscribed issue at 100p per share, a 14% premium to 31 December EPRA NAV and therefore non-dilutive. By mid-year, £66.5m had been applied to completed acquisitions and development investment of new acquisitions and development commitments. Additionally, two interest rate swap contracts (total nominal value £88.0m) were “re-couponed” such that the average effective rate to be paid by PHP was reduced from 4.79% pa to 0.87% pa with effect from November 2016. The total interest saving is £16.4m between the November 2016 re-couponing and the 2021 maturity, requiring a one-off payment of £14.5m in H116. The balance of capital issue proceeds have been used to reduce outstanding revolving debt balances pending further investment. The average cost of debt was 4.49% at 30 June (31 December: 4.67%) and the LTV was 53% at 30 June 2016 (31 December: 62.7%) with interest cover of 2.0 times, and 94% of debt cost fixed or hedged.

Attractive property niche

Background and strategy

PHP is a UK real estate investment trust (REIT) and a leading long-term investor in modern, flexible, purpose-built, healthcare facilities. The majority of these are leased to general practitioners (GPs), National Health Service (NHS) organisations, and other associated healthcare providers such as pharmacies and dentists. Investment is targeted at assets that can generate long-term rental income with scope for capital gains. Currently, all portfolio assets are in the UK, however, the company has taken its first steps within the RoI, a market that has very similar characteristics to the UK while offering the potential for enhanced risk-adjusted returns.

PHP has a long-term strategy to grow the portfolio through asset management of the existing properties and selected acquisitions, at all times ensuring the assets are fit for purpose and able to satisfy evolving healthcare needs over the long term. Let properties are acquired from a range of investors, provided the underlying occupational leases and other property fundamentals meet PHP’s investment criteria. Each potential investment is evaluated for its income and asset value growth potential. In particular PHP seeks possibilities for extending the term of the underlying leases and scope to add to the income and value from providing additional space and facilities in the future. In addition to suitable existing let facilities, PHP targets new developments, often funding the development on a pre-let basis and agreeing to acquire them at completion. It is not a developer but works with a range of experienced development partners as well as with healthcare bodies and healthcare professionals to procure newly built premises. The group finances its portfolio with a mix of equity and debt, the proportions of which are kept under regular review to optimise risk-adjusted returns to shareholders over the long term. Debt facilities are varied, accessing both traditional bank lenders and debt capital markets in the form of unsecured retail bonds and secured corporate bonds. Facilities are closely monitored to target a spread of providers and range of maturities to ensure continuity and availability that match the longevity of income streams.

The primary healthcare property sector is a specialist sector alongside the broader mainstream commercial property sub-sectors (offices, retail, industrial). As well as having good growth prospects that are effectively immune to the economic cycle, the key factors that differentiate it from the broad sector are:

Long leases at inception. Typically 20-25 years, with upwards-only rent reviews.

A strong tenant covenant. The NHS funds c 90% of PHP’s UK rental income, either as tenant or through GP cost reimbursement. The HSE will be responsible for 60-75% of RoI rental income.

Minimal vacancy (typically less than 1% for PHP).

The company was founded by the current managing director, Harry Hyman, in 1995 and began operations with the acquisition of a small portfolio of four GP surgeries. It floated on the AIM market of the London Stock Exchange (LSE) in 1996, moved to the Main Market of the LSE two years later, and converted to REIT status in 2007. PHP has a proven record of successfully investing in the sector. By 30 June 2016, the portfolio had reached 292 properties with a value of £1,198m and PHP has delivered 20 years of unbroken dividend growth since launch and an average annual NAV total return (the change in NAV plus dividends) of c 11% since listing in 1996.

Highly efficient external management

The structure of PHP’s external management arrangements has enabled the company to generate one of the lowest EPRA cost ratios in the UK REIT sector. The EPRA cost ratio was 11.5% in H116, unchanged from 2015 as a whole and down from 11.6% in H115.

Exhibit 1: EPRA cost ratio

£m unless otherwise stated

H116

H115

2015

Gross rent less ground rent

32.4

30.8

62.7

Direct property expense

0.4

0.4

0.8

Administrative expenses

3.5

3.4

6.8

Less: ground rent

(0.1)

Less: other operating income

(0.2)

(0.2)

(0.3)

EPRA costs (including direct vacancy costs

3.7

3.6

7.2

EPRA cost ratio (%)

11.5%

11.6%

11.5%

Source: Company data

The board of PHP has retained Nexus Tradeco (Nexus) as the adviser, to provide property advisory and management services, including the services of the managing director and deputy managing director/finance director, Harry Hyman and Phil Holland (see below), as well as administrative and accounting services. Nexus owns c 2.7% of PHP, which contributes to an alignment of interest between the two and PHP shareholders.

At the end of 2015, the Nexus property and admin team employed 25 members of staff, including nine chartered surveyors and five chartered accountants.

Nexus receives a property advisory fee payable based on the gross net assets of PHP’s portfolio, calculated on a sliding scale as shown in Exhibit 2. Importantly, incremental asset growth lowers the average fee, which in combination with fixed administration costs (see below) means that the cost ratio should continue to decline as the portfolio grows further.

Exhibit 2: Property services fee structure

NAV (£)

Fee (%)

Full fee for £1.5bn portfolio (£)

First 250m

0.500

1,250,000

250m - 500m

0.475

1,187,500

500m - 750m

0.400

1,000,000

750m - 1bn

0.375

937,500

1bn - 1.25bn

0.325

812,500

Above 1.25bn

0.300

750,000

Average/total

0.396

5,937,500

Source: Company data. Note: Any additional payments for non-standard property services are capped at 10% of the total annual property services fee.

In addition, Nexus receives a fixed annual fee in respect of administrative and accounting services, c £904k from 1 May 2016. This fixed fee may be adjusted (up or down) by up to 5% pa subject to movements in RPI.

Nexus is also entitled to a performance incentive fee (PIF), which is set at 11.25% of annual IFRS NAV total return in excess of 8%. Where total performance has fallen short of 8% in any one year, the “deficit” must be made up in subsequent years before any PIF is paid. As at 1 January 2016, there was a deficit of £12.5m that must be made up in the net asset value before any PIF becomes payable.

The board

PHP is governed by an eight-member board consisting of two executive and six independent non-executive directors: the two executive directors are Harry Hyman and Phil Holland. Harry Hyman is the managing director and the founder of both PHP and Nexus Tradeco. Phil Holland, the finance director and deputy managing director, is similarly employed at Nexus. PHP contracts for the services of Harry Hyman and Phil Holland with Nexus under the advisory agreement for which Nexus receives the directors’ fees. Alun Jones became the independent non-executive chairman in April 2014, having been appointed to the board in 2007. He is a chartered accountant and has previously served on PwC’s UK and global supervisory boards as well as the financial reporting review panel. The five additional non-executive directors (Steven Owen, Mark Creedy, Nick Wiles, Geraldine Kennel and Dr Ian Rutter) all bring a wealth of property, financial and management experience to the board.

Brief biographies are provided on page 16.

The sector drivers and growth prospects

In both the UK and the RoI, primary care is the foundation of the healthcare system and GPs act as the “gatekeepers” or first point of access to healthcare services. There are more than 1.3 million GP visits daily in the UK (source: Royal College of Practitioners, January 2015), representing c 90% of all NHS contacts with patients. The NHS and its RoI equivalent, the HSE, face increasing pressures from population growth and an ageing population, living longer with more medical conditions. The UK population is expected to grow from 64.6 million in 2014 to 74.3 million in 2039 (source: ONS), with the share of those aged 65 and over growing from 17.7% to 24.3% (11.4 million to 18.0 million). The Irish Central Statistics Office (CSO) forecasts a rise in total population of 13.4% between 2011 and 2031 (4.6 million to 5.2 million) and for the share of over-65s to rise from 11.6% to 19.1%.

In addition to simply meeting this expected additional demand for healthcare services, both the NHS and the HSE seek to increase the range of services that GPs are able to provide, outside the hospital sector, in local community settings, integrated with other healthcare services. In addition to improved and more convenient access to services for patients, the shift in delivery is expected to achieve overall cost efficiencies and ease the burden of budgetary constraints on the system as a whole. It has been estimated that every £1 increase in GP spending has the potential save £5 in other areas of the NHS, including the cost of hospital admissions (source: Royal College of GPs/Deloitte, 2014).

An obstacle to change and an opportunity for long-term investors in modern, purpose-built premises like PHP’s is that a large share of the current primary care estate, in both the UK and the RoI, is incapable of adapting to meet the new demands. Much remains owned directly by GPs, often residential conversions, with little or no investment in recent years, and with little or no opportunity to adapt or expand. It has been estimated that more than 50% of the primary care estate is more than 30 years old (source: Savills/EC Harris) and in a 2014 survey by the BMA, 70% of GPs stated their premises are too small to be able to deliver enhanced and additional services, 52% said their premises had seen no investment or refurbishment in the past 10 years, and the majority said that their premises are too small to be able to deliver training and education. Aside from being physically inadequate, such premises are simply unable to accommodate the trend to GP practice consolidation or multi-practice accommodation, both ways of allowing GPs to adapt to the new service demands, nor of accommodating the extra 5,000 GPs planned between 2015 and 2020 as part of the drive to 24/7 GP delivery. Modern, flexible premises of the type that PHP and others invest in will be key to the successful delivery of expanded, locally delivered and integrated services. According to the BMA, there were c 9,800 GP practices in the UK (c 43,000 GPs) as of July 2014. PHP estimates that these GPs operate from c 10,000 premises. Of those, less than 800 larger, modern, purpose-built premises are owned by the three listed primary care investment companies (PHP, MedicX Fund and Assura). Even allowing for ongoing consolidation of smaller GP practices into larger groups, the implied future demand for investment is very significant. However, if the NHS commitment to this investment is restricted to rent reimbursement with capital provided by long-term investors, the financial burden on the NHS, in the form of rent, would be a much more manageable 5-6% of the capital investment required.

NHS: Five-Year Forward View and GP Forward View

The structure of the NHS in England has gone through a number of significant changes in recent years. In 2013 Clinical Commissioning Groups (CCGs), led by GPs, replaced Primary Care Trusts as the regional authorities responsible for delivering primary care. At the same time, NHS Property Services was created to manage, maintain and improve the NHS property estate. The CCGs assumed greater control of NHS budgets, able to spend any savings they make in one field in others of their own choosing. The direction of travel of NHS changes is extremely positive in terms of future investment in the modernisation of the primary healthcare estate, although as new structures were bedding down, as plans were made and financial resources garnered, NHS approvals for new schemes have been unusually slow to come through. This now appears to be changing.

NHS England published its Five Year Forward Review (NHS Review) in October 2014, a strategic plan for the development of UK healthcare services. Significantly, it reiterated that “the foundation of NHS care will remain list-based primary care” (NHS emphasis) and set out plans for additional investment in primary care in England to provide more services within a local community setting.

CCGs were asked to submit Strategic Estate Plans (SEPs) by 31 December 2015, for review by 31 March 2016.

The government supports the aims of the NHS Review and has also stated its objective to improve patient access to GPs, moving to a 24/7 service. These ambitions have been supported with increased resources, and the November 2015 Spending Review allocated an additional £10bn of investment funding to NHS England (£6bn to be provided by the end of the 2016/17 financial year). In return the NHS is tasked with generating internal cost savings of £22bn pa under the NHS Review, a target that increased emphasis on cost-effective community-based primary care should be able to contribute to.

In April 2016 NHS England published its General Practice Forward View (GP Review), which provides details of its strategic plans for delivering on this agenda for general practice, including plans for investment in staff, technology and premises. These include an increase of 25% in the GP budget, the recruitment of an additional 5,000 GPs over five years, and a commitment to out of hours care, developing clinical hubs and urgent care services.

Separately, the government has established an Estates and Technology Transformation Fund (ETTF) specifically to improve primary care infrastructure. It will disburse £900m this autumn and both CCGs and GPs submitted bids by the end of June 2016. While this fund will not have a direct impact on PHP, the awards will support approvals where PHP capital will be invested along with ETTF funds. We believe it demonstrates the political will to improve the primary care estate and therefore supports the view that once SEPs have been reviewed, CCGs, the NHS more generally and wider government will support their implementation. This in turn bodes well for PHP, whose tenants have submitted 28 proposals for funding from the ETTF, which will see PHP invest capital totalling £15.4m, generating additional rent of £1.02m and adding a weighted average of 13.4 years to the unexpired leases on the relevant properties.

Meanwhile, drafts of some SEPs are becoming available and lead us to expect an increase in primary care developments in England over the next 18 months. As a result of SEPs being implemented, most likely from mid-2016 onwards, we anticipate a rise in approvals for new primary care developments. As an example, three CCGs in Nottinghamshire had assessed their collective estate by November, noting that “the strategic direction for premises for a number of years has been for the NHS to support larger developments for financial and clinical service reasons. In larger practices there is potential for a greater range of services to be offered to patients, a greater range of clinical expertise, more opportunities for peer review and economies of scale which present opportunities for wider clinical multi-disciplinary teams. In addition, larger buildings provide more opportunities for moving services from secondary care to primary care.” They specifically identified at least one health centre that needed to be replaced and have named that as the CCGs’ top priority.

HSE: Implementing the RoI’s health strategy

Ireland’s HSE faces similar challenges to the NHS and the Irish Department of Health (DoH) has launched a strategy to meet the future needs of the population. Until recently, primary care in Ireland was provided privately by GPs. In late 2012 the HSE introduced a new healthcare strategy, a key element of which was the establishment of a single tier primary care service, free and universal. So far, only those under six and over 70 have been given access to primary care paid for by the state. By 2019 it is planned that it will be available to all.

The mainstay of primary care in Ireland, as in the UK, is the GP, but in Ireland they have been fee charging and their rents and rates have not been reimbursed by the government. As a result, private investment in primary care has been inhibited.

The new strategy has established a number of state-funded Primary Care Teams, each responsible for a different geographic area and comprising a range of services such as community and public health nursing teams, home helps, mental health services, social workers and dental care. Currently, these providers are not necessarily all co-located but there are opportunities to improve efficiency and service delivery if this can be achieved. To that end the DoH has a Primary Care Centre (PCC) building programme with specific goals: nine PCCs were delivered in 2015 and 28 are planned for 2016 and the first half of 2017. When the targets were published at the end of 2014, there were around 30 centres under construction with a further 50 planned. The HSE will be the anchor tenant in each one, occupying 60-75% of the building on a 25-year lease, with GPs and pharmacies taking the remainder. Planned PCCs range from 1,500 to 5,000sqm, which is large compared to most of PHP’s portfolio (average size 1,227sqm; the average size of new assets in 2015 was 1,651sqm). Although the rental covenant will not be as strong as in the UK, where the government underpins 91% of rents, the tenant mix should provide a secure income stream albeit with slightly more risk of vacancy than in the UK. We note that HSE rent reviews will be every five years rather than every three as is standard in the UK. At 30 June PHP had €14m of Irish transactions agreed and in solicitors’ hands and €40m under offer, which includes the €6.7m Irish commitment made since.

Review of the portfolio

Modern, diversified portfolio

At 30 June 2016 PHP had portfolio of 292 properties, all in the UK (PHP entered into its first conditional contract to acquire a primary care centre under development in the RoI after the period end), with a total value of £1.2bn (an average of £4.1m per property), of which three were under development (two since completed). The contracted rent roll was £66.9m with 91% of the rents being paid directly (c 21%) or indirectly (via GP reimbursement, c 69%) by the NHS, with the balance coming mainly from pharmacies co-located with GPs’ surgeries (and thereby provided with a consistent stream of revenues). As is common in the sector, there is effectively no vacancy with 99.7% of space let at 30 June. Lease terms are long, typically 20-25 years at inception, and PHP has an average unexpired term across the portfolio of 14.1 years.

Exhibit 3: Portfolio by value

Exhibit 4: Portfolio by unexpired lease

Source: Company data as at 30 June 2016

Source: Company data as at 30 June 2016

Exhibit 3: Portfolio by value

Source: Company data as at 30 June 2016

Exhibit 4: Portfolio by unexpired lease

Source: Company data as at 30 June 2016

The portfolio is geographically diverse with assets well spread throughout the mainland UK. We look to the average age of the portfolio (11 years compared with 65% of the primary care estate in the UK being more than 20 years old and 50% more than 30 years old), together with the average size of the assets (and low proportion of small sized assets) as evidence of management’s focus on generating sustainable long-term returns from flexible, modern properties.

Exhibit 5: Portfolio by rent source

Exhibit 6: Geographic split of rents

Source: Company data as at 30 June 2016

Source: Company data as at 30 June 2016

Exhibit 5: Portfolio by rent source

Source: Company data as at 30 June 2016

Exhibit 6: Geographic split of rents

Source: Company data as at 30 June 2016

Upwards-only rent reviews

Rent reviews in the UK are effectively upwards-only and take one of three forms: fixed uplifts (c 6% of rents), RPI-linked (c 19%) and open market (at the option of the landlord, c 75%). The majority of reviews are on a three-year basis (77%), with the balance on either one-year (10%) or five-year (13%) cycles. In the RoI, the HSE has indicated that it will enter into 20-25 year leases with five-yearly reviews set by reference to CPI, but rents may go down as well as up.

The weighted average rent increase on completed rent reviews in H116 was 1.0%, down on the 1.1% seen in H115 but up on the average for FY15 as a whole. Rental growth has declined in recent years due to the impact of low inflation on RPI-linked growth, and due to muted growth of open market rents.

Exhibit 7: Rent growth history

Source: Company data, Edison Investment Research

In H116 the weighted average increase on fixed uplift lease reviews completed was 2.65%, similar to the level seen in FY14 and FY15. RPI uplifts averaged 1.65%, similar to FY15 but lower than FY14. Open market reviews saw a c 0.7% increase, very slightly ahead of FY15 but well down on recent years. Open market reviews aim to set the rent at current market level, defined as what would be paid by a free and willing tenant to a landlord in that area. The decision is that of the district surveyor, allowing for a range of factors including the size, condition, amenity and location of the premises as well as terms of the lease itself. The reorganisation of the NHS structures in 2014 has slowed the decision making process that would sanction the development of new primary healthcare facilities, and this has restricted the opportunity for land and building costs, to be reflected in the rents set for modern, well equipped buildings. As the pace of new development gradually increases there is a widespread expectation that this will support market rent growth. If not, there is a risk that the private investment that is needed to support the modernisation of the healthcare estate could become restricted.

Favourable funding conditions mitigate yield tightening

Demand for attractive primary healthcare properties has remained strong, which is continuing to compress yields. While revaluations have helped increase NAV, yield compression continues to make it more expensive to acquire assets and new income streams, particularly in the UK. Much of the competition comes from institutional investors seeking larger assets and portfolios, which some market participants indicate are being bought at yields below 5%. PHP has continued to be selective in its acquisitions, with access to transactions doubtless supported by its track record and established market relationships, and it has extended its investment universe to the RoI where risk-adjusted yields compare favourably. Meanwhile a combination of good funding conditions and PHP’s reducing incremental administrative costs are maintaining a healthy spread between property yields and costs. By way of illustration for the UK, taking the current 5.21% net initial yield on the portfolio, the incremental management fee of 0.325% for PHP and adjusting for funding costs (the 10-year Libor swap rate and PHP’s incremental margin on current facilities), there is a positive spread of 2.185%. With Irish net initial yields higher at c 7% and the 10-year Euribor swap rate at 0.25%, the illustrative spread is nearer 4.6%.

Exhibit 8: UK net margin over funding cost

Exhibit 9: RoI net margin over funding cost

Source: Company data

Source: Company data

Exhibit 8: UK net margin over funding cost

Source: Company data

Exhibit 9: RoI net margin over funding cost

Source: Company data

Financials and estimate revisions

We have updated our forecasts for the FY16 interim results that were recently released, as well as the April equity issue that was partly deployed in H116 property acquisitions.

The £54m invested in property additions in H116 was ahead of the rate that we had expected and it was all into immediately income-generating assets (as opposed to development funding commitments). We had assumed £32.5m of new commitments in H116 (of which £7.5m immediately income generating) and £65.0m for the year (£15.0m immediately income generating). We have maintained our investment commitment assumptions for H216, increasing the full year total from £65m to £86.3m and have also maintained FY17 at £95.0m. Both assumptions include a higher share of immediately income generating assets (£17.5m up from £10m in H216 and £17.5m up from £15m in FY17). PHP has indicated a current pipeline of opportunities of £82.1m in the UK and €91.4m (c £79m) in Ireland. Of those roughly 40% are in very advanced stages (in solicitors’ hands or shortly to be).

We have made no change to our assumption of average rent increases of 1.0% in FY16 and 1.5% in FY17. The FY17 increase reflects the expectation of accelerated NHS development, also evident in our forecast commitments.

Our forecasts for revaluation movements are based on our expectation of rental growth at an unchanged valuation yield. The H116 revaluation gain was above that assumed in our forecasts as a result of the further H116 tightening yields. We have adjusted for this but continue to make no assumption on yield movements.

Exhibit 10: Estimate revisions

Revenue (£m)

EBITDA (£m)

EPRA EPS (p)

DPS (p)

Dividend cover

EPRA NAVPS (p)

Old

New

% diff

Old

New

% diff

Old

New

% diff

Old

New

% diff

Old

New

% diff

Old

New

% diff

12/16e

66.2

67.2

2%

58.2

59.1

2%

5.2

4.8

-7%

5.125

5.125

0%

102%

101%

-1%

90.3

91.6

1%

12/17e

71.1

72.9

2%

62.6

64.2

3%

5.4

5.4

0%

5.250

5.250

0%

103%

103%

0%

94.3

94.8

0%

Source: Company data, Edison Investment Research

As a result of the capital raising our forecast for net debt is lower than previously. Allowing for property investment our forecasts point to £664m of net debt at the end of FY16 (down from £757m previously) and £757m at the end of FY17 (down from £853m). FY16e EPRA earnings are increased from £23.3m to £27.1m and FY17e EPRA earnings from £24.2m to £32.3m. For FY16, estimated EPRA EPS is lower, reflecting the increase in the average number of shares and the delay in fully deploying the proceeds; our FY17 EPRA EPS forecast is unchanged. Although FY16e EPRA EPS is below the headline dividend, the new shares do not qualify for the first two quarterly dividends and this is why the total cash dividends paid that we forecast in the year are covered by forecast earnings.

Management actively manages the liability side of the balance sheet as well as the asset side. PHP is funded through a blend of equity and external debt, balanced with the aim of enhancing shareholder returns. A key objective for management is to ensure the group maintains access to appropriate debt facilities to be able to maintain growth. The group had total debt facilities of £749.8m at 30 June 2016 and the principal value of drawn debt was £634.8m leaving £115m undrawn (or £109.8m after development commitments and allowing for cash). The debt is diversified by source, substantially fixed or hedged against interest rate increases, and relatively long term. In addition to bank facilities, debt facilities include a £70m secured bond maturing in 2025, a £75m retail bond due in July 2019, and £82.5m (nominal value) convertible bonds due in May 2019 with a conversion price of 97.5p. Around 75% of the drawn debt is secured and the balance is unsecured, providing additional funding flexibility.

Exhibit 11: Debt mix (£m)

Exhibit 12: Interest rate swap protection

Source: Company data as at 30 June 2016.

Source: Company data, Edison Investment Research

Exhibit 11: Debt mix (£m)

Source: Company data as at 30 June 2016.

Exhibit 12: Interest rate swap protection

Source: Company data, Edison Investment Research

More than half of the debt is at fixed interest rates. The company’s policy is to maintain floating rate interest exposure between 20% and 40% of total debt, which it manages using interest rate swap contracts to hedge floating rate exposure. At 30 June, £126m of swaps were in effect and a further £60m came into effect in July and August. This swap protection covers nearly 80% of the 30 June variable rate debt with the effect that c 94% of all debt is fixed or hedged. The weighted average swap rate at 30 June was c 4%, although this will change in future as the new swaps come into force and as swaps covering £88m of debt are re-couponed in November to 0.87% from 4.79%.

Valuation

Attractive and secure yield

PHP returned to full dividend cover in H215, and this increased further in H116. Our forecasts indicate full cover through the FY16 and FY17 forecast period.

Exhibit 13: PHP dividend per share history

Source: Company data, Edison Investment Research. Note: Adjusted for 4:1 share split in November 2015.

As a UK REIT, PHP is required to pay distributions of at least 90% of the group’s rental profit (calculated by reference to tax rules rather than accounting standards). In addition to a high pay-out ratio, PHP has grown the dividend in each of the 20 years since listing.

Exhibit 14: PHP dividend yield compared with EPRA NAREIT UK sector

Source: Bloomberg, as at 15 August 2016

High and growing dividends are supported by long-term cash flows underpinned by long leases to the UK government, via the NHS, being the underlying tenant of 90% of the UK portfolio. For the current year consensus forecasts indicate 5.125p per share in dividends, subject to unforeseen circumstances, a 2.5% increase on 2015. This represents a yield of 4.7% on the current share price, versus 3.9% for the FTSE All Share and 0.57% on a 10-year gilt. PHP’s yield premium versus the EPRA NAREIT sector is broadly in line with its long-term average and has been reducing in recent months as investors have become more cautious about the prospects for the broader UK commercial property sector. Net rental income is a significant element of commercial (and healthcare) property returns over time (c 75%). However, because healthcare property is less economically sensitive, displays consistently high levels of occupancy and is less susceptible to speculative development, returns tend to show much less volatility than the commercial sector as a whole.

Yield tightening supporting NAV

Net asset value per share was 90.4p on an EPRA basis (82.5p on an IFRS basis) at the end of June 2016, up 3.1% (6.5%) from the end of 2015. The EPRA NAV is adjusted for the fair value liability of interest rate swaps and changes in the fair value of the convertible bond. At a share price of 112p, the shares trade at a 24% premium to EPRA NAV, slightly above the 10-year average of 16%. We note that the current yield on the UK 10-year gilt yield (0.57%) is well below its 10-year average of 3.0%.

Exhibit 15: Comparison of PHP net initial yield and 10-year UK gilt

Source: Company data, Bloomberg, Edison Investment Research

As shown in Exhibit 15 above, net initial yield on valuation has declined over the last five years and tightened further by 11bp to 5.21% in H116. It is our standard practice not to include an assumption of yield changes in our forecasts (our forecast revaluation gains are derived from rent increases on an unchanged yield) but further compression is entirely possible despite increased nervousness in the broad core UK commercial property market since the EU referendum vote. Primary healthcare property assets have traditionally showed much less price/yield volatility than the broad commercial market over the cycle, with yields moving between c 5.0% and c 6.25% over the past 10 years (source: IPD data). Although the current yield on PHP’s portfolio is not much above the historical floor, we note strong appetite for such assets, especially larger assets where institutional investors are keen to lock in long-term RPI linked growth in this low interest rate environment. We estimate that a further 5bp tightening to 5.16% would increase EPRA NAV of the portfolio as at 30 June 2016 by 2p and a reduction to 5% would add 8.8p per share to 30 June EPRA NAV.

PHP performance in context

During H116 PHP generated a total return on its property assets (net rental income plus valuation movements) of 4.2% and, with the benefit of gearing, the NAV total return was 6.0%. For the FY15 year as a whole, the returns were 9.7% and 16.3% respectively. Net revaluation gains in 2015 were £39.8m and in the first half of 2016 were £15.5m. Exhibit 16 gives a longer-term perspective on PHP’s property returns and those for the sector as a whole for various periods up to the end of 2015, the last period for which we have data available. The nine-year data begin at the end of 2006. Over this period Primary Healthcare returns have exceeded those of the mainstream commercial property market, both as measured by IPD. More striking is that within this period commercial property returns have been significantly more volatile. The broad sector saw values decline by c 42% from the pre-financial crisis peak in 2007 to the trough in March 2009. It has seen a significant upswing since. As expected, healthcare property values were much more defensive in the downturn and have been lagging the broader sector in the post-2009 upswing.

Exhibit 16: IPD All Property Index (total return)

To 31 December 2015

One year

Three years

Five years

Nine years

IPD EPRA NAV total return

16.3%

11.2%

8.7%

5.0%

PHP total property return

9.7%

8.9%

8.4%

IPD Primary Healthcare Property

10.5%

9.2%

8.6%

7.3%

IPD All Healthcare Property

10.4%

8.3%

7.0%

6.4%

IPD All Commercial Property Index

13.1%

13.8%

10.5%

4.4%

Source: Company data, IPD, Edison Investment Research. Note: Returns for periods above one year are average annualised returns. The nine-year data is the earliest available for the IPD Healthcare Index.

While net rental income is a significant element of commercial (and healthcare) property returns the reason for this difference in volatility is the much lower economical sensitivity of healthcare property, with consistently high levels of occupancy and almost no speculative development. Over the last five years PHP’s property return has performed similarly to the IPD Primary Healthcare Index, and the benefits of gearing mean that the total NAV return generated by PHP’s assets has been higher.

Sensitivities

As a long-term investor (not developer) operating in a sector with long leases, predominantly government backed, with minimal vacancy and (in the UK) upwards only lease adjustments, supported by predominantly fixed-cost debt, we view PHP as relatively low risk. There are nevertheless a range of factors that could impact the business, especially over the longer term, including structural changes in the markets in which the group operates, changes to government health and fiscal policies, general economic and monetary conditions, and operational performance.

Market environment.

As discussed above, the demand for healthcare in both the UK and the RoI seems set for further growth, while government and health service planning in both countries puts primary healthcare at the centre of measures to both improve delivery and generate overall efficiencies. Primary healthcare estates are in need of substantial modernisation and upgrading to meet this demand.

Attractive risk adjusted yields have attracted new investors to the sector, helping to drive down yields, especially for larger let properties, and have increased the cost of acquisition. PHP has a strong reputation and track record in the market and has continued to successfully acquire let properties in the UK. Its formal and informal developer relationships leave it well placed to benefit from the gradual increase in development activity that is expected. Entry into the RoI market provides additional access to attractively priced properties.

Government policy. While changes cannot be ruled out over the longer term, the UK government and all major parties are in support of NHS five-year planning, which includes a larger, community-based role for primary care, with 24/7 access to GP services and supported by increased funding. The RoI government is similarly restructuring its primary care provision.

General economic and monetary conditions.

The non-cyclical nature of the sector reduces the impact of the wider economy, and we would include the impact of Brexit in this statement.

Continued access to debt at a suitable cost relative to rental income remains an important factor for asset growth and cash flow. Recent conditions have been favourable for both access and cost and the group maintains a broad range of funding access.

Exhibit 17: Financial summary

£000s

2013

2014

2015

2016e

2017e

Year end 31 December

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

41,982

59,985

63,115

67,231

72,854

Cost of Sales

(398)

(723)

(852)

(846)

(917)

Gross Profit

41,584

59,262

62,263

66,384

71,937

Administrative expenses

(6,080)

(6,782)

(6,807)

(7,263)

(7,706)

EBITDA

 

35,504

52,480

55,456

59,121

64,231

Other income and expenses

638

0

0

0

0

Non-recurring items

(2,702)

(2,426)

0

0

0

Net valuation gain on property portfolio

2,313

29,204

39,767

21,465

17,962

Operating profit before financing costs

 

35,753

79,258

95,223

80,586

82,192

Net Interest

(26,016)

(34,275)

(33,727)

(32,068)

(31,928)

Non-recurring finance income/expense

0

0

0

0

0

Early loan repayment fees

(950)

(1,187)

0

(24)

0

Fair value gain/(loss) on interest rate derivatives and convertible bond, and swap amortisation

11,432

(6,916)

(5,464)

(2,650)

0

Profit Before Tax

 

20,219

36,880

56,032

45,844

50,264

Tax

1

0

0

0

0

Profit After Tax (FRS 3)

 

20,220

36,880

56,032

45,844

50,264

Adjusted for the following:

Net gain/(loss) on revaluation

(2,313)

(29,204)

(39,767)

(21,465)

(17,962)

Fair value gain/(loss) on derivatives & convertible bond

(11,432)

6,916

5,464

2,650

0

Profit on termination of finance lease

(638)

0

0

0

0

Early loan repayment fees

950

1,187

0

24

0

Issue costs of convertible bond

0

2,426

0

0

0

EPRA basic earnings

 

6,787

18,205

21,729

27,053

32,302

Period end number of shares (m)

441.9

445.1

446.3

597.9

599.4

Average Number of Shares Outstanding (m)

356.5

444.2

445.5

559.6

598.6

Fully diluted average number of shares outstanding (m)

356.5

496.6

530.2

644.2

683.2

EPS - fully diluted (p)

 

5.7

7.9

11.2

7.4

7.6

EPRA EPS (p)

 

1.9

4.1

4.9

4.8

5.4

Dividend per share (p)

4.750

4.875

5.000

5.125

5.250

Dividend cover

41%

84%

98%

101%

103%

BALANCE SHEET

Fixed Assets

 

942,020

1,026,232

1,100,621

1,225,476

1,339,688

Investment properties

941,548

1,026,207

1,100,612

1,225,476

1,339,688

Net investment in finance leases

0

0

0

0

0

Derivative interest rate swaps

472

25

9

0

0

Current Assets

 

14,052

17,740

7,034

8,460

10,708

Trade & other receivables

4,764

5,668

4,153

4,299

4,598

Net investment in finance leases

0

0

0

0

0

Cash & equivalents

9,288

12,072

2,881

4,161

6,109

Current Liabilities

 

(39,635)

(33,065)

(34,864)

(34,156)

(35,200)

Term loans

(3,843)

(711)

(862)

(779)

(779)

Trade & other payables

(16,269)

(14,244)

(16,099)

(14,976)

(16,020)

Derivative interest rate swaps

(7,566)

(5,802)

(4,734)

(4,369)

(4,369)

Deferred rental income

(11,934)

(12,308)

(13,169)

(14,032)

(14,032)

Other

(23)

0

0

0

0

Long Term Liabilities

 

(614,052)

(701,777)

(727,431)

(701,472)

(796,472)

Term loans

(460,185)

(437,022)

(460,550)

(432,799)

(527,799)

Bonds

(132,408)

(229,543)

(236,328)

(234,656)

(234,656)

Derivative interest rate swaps

(21,459)

(35,212)

(30,553)

(34,017)

(34,017)

Net Assets

 

302,385

309,130

345,360

498,307

518,723

Derivative interest rate swaps

28,553

40,989

35,278

38,386

38,386

Change in fair value of convertible bond

0

4,462

10,931

10,931

10,931

EPRA net assets

 

330,938

354,581

391,569

547,624

568,040

IFRS NAV per share (p)

68.4

69.5

77.4

83.3

86.5

EPRA NAV per share (p)

74.9

79.7

87.7

91.6

94.8

CASH FLOW

Operating Cash Flow

 

36,682

49,020

57,145

58,352

64,975

Net Interest & other financing charges

(30,430)

(49,633)

(32,337)

(32,307)

(31,928)

Tax

0

(23)

0

(51)

0

Acquisitions/disposals

(54,731)

(54,396)

(29,477)

(102,620)

(96,250)

Net proceeds from issue of shares

65,232

17

(139)

145,305

0

Equity dividends paid (net of scrip)

(16,130)

(20,688)

(21,083)

(25,070)

(29,848)

Other (including debt assumed on acquisition)

(211,273)

7,647

(13,764)

(12,823)

0

Net Cash Flow

(210,650)

(68,056)

(39,655)

30,786

(93,052)

Opening net (debt)/cash

 

(376,498)

(587,148)

(655,204)

(694,859)

(664,073)

Closing net (debt)/cash

 

(587,148)

(655,204)

(694,859)

(664,073)

(757,125)

Source: Company data, Edison Investment Research

Contact details

Revenue by geography

5th Floor
Greener House
66-68 Haymarket
London

SW1Y 4RF

0207 104 5599

www.phpgroup.co.uk

Contact details

5th Floor
Greener House
66-68 Haymarket
London

SW1Y 4RF

0207 104 5599

www.phpgroup.co.uk

Revenue by geography

The board

Chairman: Alun Jones

Managing Director: Harry Hyman

Mr Jones is a chartered accountant who was a partner at PricewaterhouseCoopers until he retired in 2006. He had previously been a member of PwC’s UK and global supervisory boards and served on the financial reporting review panel.

Mr Hyman founded PHP and its property adviser Nexus in 1994 and is the managing director of both. He is a chartered accountant and the non-executive chairman of Summit Germany, an AIM quoted company that invests in German commercial property.

Finance Director: Phil Holland

Non-executive director: Mark Creedy

Mr Holland is a chartered accountant who was previously CFO of Natixis Capital Partners, a private real estate fund manager with commercial real estate interests across Western Europe. He is a non-executive director of Network Housing Group.

Mr Creedy is director of fund management at UNITE Group. He was managing director of the property fund management subsidiary of Legal & General Investment Management from 2002 to 2007 and managing director of Chartwell Land before that. He was also a non-executive director of B&Q.

Non-executive director: Geraldine Kennell

Non-executive director: Dr Ian Rutter OBE

Ms Kennell joined the board in April 2016 with more than 20 years’ experience in private equity, recently as a partner at Silverfleet Capital LLP. She has served on the boards of a number of companies, including Ivy Topco Limited (holding company of the Ipes group of companies), TMF Group Holdco BV, Link Financial Limited and Birthdays Limited.

Dr Rutter has been a GP since 1980 and is currently senior European faculty head of the Institute of Healthcare Improvement in Boston, Massachusetts. He is a former CEO of North Bradford and Airedale PCTs. He has worked at the Department of Health as clinical lead in the policy and strategy unit and as deputy national director of Primary Care.

Non-executive director: Steven Owen

Non-executive director: Nick Wiles

Mr Owen is a chartered accountant. He was deputy CEO and a partner at Wye Valley Partners LLP, a commercial real estate and asset management business, and finance director of Brixton until it was acquired by Segro in 2009.

Mr Wiles joined the board in April 2016 with more than 20 years of experience in banking and financial markets. At Cazenove & Co he was a partner, becoming vice chairman of JP Morgan Cazenove, and more recently he was chairman of UK investment banking at Nomura. He was a non-executive director of Strutt & Parker and is currently non-executive chairman of PayPoint.

Principal shareholders

(%)

Investec Wealth & Investment

5.2

Unicorn Asset Management

4.5

Blackrock

3.9

CCLA Investment Management

3.9

Troy Asset Management

3.7

Investec plc

3.2

Charles Stanley

3.0

Hargreaves Lansdown

3.0

Companies named in this report

MedicX Fund (MXF), Assura (AGR)

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Primary Health Properties and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers’ exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Primary Health Properties and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers’ exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

More on Primary Health Properties

View All

Latest from the Real Estate sector

View All Real Estate content

Elk Petroleum — Update 26 August 2016

Elk Petroleum

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free